Four-strain probiotic exerts a positive effect on irritable bowel syndrome symptoms occurring in inflammatory bowel diseases in absence of inflammation (train-IBD trial)

doi:10.4292/wjgpt.v16.i2.101268

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-2) series.

Item

Count

PDF

HTML

Figures (1-3)

Tables (1-2)

Sum=7

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=1

Jun 5, 2025 (publication date) through Jun 3, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Pharmacology and Therapeutics

ISSN

2150-5349

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Gastrointest Pharmacol Ther. Jun 5, 2025; 16(2): 101268
Published online Jun 5, 2025. doi: 10.4292/wjgpt.v16.i2.101268

Four-strain probiotic exerts a positive effect on irritable bowel syndrome symptoms occurring in inflammatory bowel diseases in absence of inflammation (train-IBD trial)

Anne Fennessy, Micheal Doyle, Anna Boland, Rachel Bourke, Anthony O'Connor

Anne Fennessy, Micheal Doyle, Anna Boland, Rachel Bourke, Anthony O'Connor, Department of Gastroenterology, Tallaght University Hospital, Dublin D24NR0A, Ireland

Author contributions: Fennessy A and O’Connor A designed the research study; Fennessy A, Doyle M, Boland A, Bourke R performed the research including recruitment and clinical assessment; Fennessy A and O’Connor A prepared the manuscript.

Institutional review board statement: The study was reviewed and approved by the SJH/TUH Joint Research Ethics Committee Institutional Review Board. Reference Number 2018/09/26.

Clinical trial registration statement: The registration identification number is 2018-003419-23.

Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

Conflict-of-interest statement: The authors have no conflicts of interest to declare.

CONSORT 2010 statement: The authors have read the CONSORT 2010 statement, and the manuscript was prepared and revised according to the CONSORT 2010 statement.

Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at oconna12@tcd.ie.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Anthony O'Connor, MBChB, MD, MRCP, MSc, Associate Professor, Doctor, Senior Lecturer, Department of Gastroenterology, Tallaght University Hospital, Belgard Rd, Dublin D24NR0A, Ireland. oconna12@tcd.ie

Received: September 9, 2024
Revised: January 16, 2025
Accepted: April 25, 2025
Published online: June 5, 2025
Processing time: 266 Days and 21.9 Hours

Core Tip

Core Tip: A four-strain probiotic is well-tolerated in patients with inflammatory bowel disease (IBD) overlap and does not lead to adverse IBD related outcomes. Adequately powered studies are required to validate our observation of a trend towards better IBS outcomes in this group.